Parabilis reports Q3 2026 results, aligns with FDA on desmoid Phase 3 design
The company said it reached FDA alignment on a global Phase 3 trial for zolucatetide in desmoid tumors and reported $1.1 billion in cash as of September 30, 2026.
SEC filing